For the U.K. based company, YouSeq’s new release is simply the next step toward making every clinically relevant target available as a ready-to-order test. YouSeq now offers what it calls the largest qPCR test menu in the world, strengthening its position as a global pioneer in ultra-broad-menu molecular testing. Each new assay detects multiple targets in a single reaction, giving laboratories faster turnaround times, richer data per run, and lower cost per datapoint.

“With this release, we remove the old idea that labs must wait for the market to supply the panels they want,” said Jim Wicks, founder of YouSeq. “Instead, they can simply select the multiplex tests they need, and we’ll build the panel for them.”

These new assays can be used individually or as part of a custom pre-plated panel service, which allows high-throughput labs to choose any combination of targets from the company’s library and have them preloaded into 96- or 384-well plates—ready to run, no pipetting or in-house assay development required.

A scalable, streamlined approach

YouSeq’s expanded menu directly addresses key bottlenecks faced by diagnostic and research laboratories:

• Multiplexing power—detect multiple pathogens, biomarkers, or variants in a single qPCR run.
• Efficiency gains—fewer wells mean less labor and higher throughput.
• Economic advantages—more datapoints per plate translate to better cost efficiency and higher revenue per shift.
• Consistency and quality—standardized assays reduce the risk and variability of in-house assay design.

By simplifying access to high-quality, high-content assays, the company is positioning itself as a turnkey partner for molecular testing labs, offering both scale and customization—qualities rarely combined in one platform.

From off-the-shelf to on-demand

The launch is about more than scale—it’s about redefining accessibility. The company’s approach blurs the line between ready-made testing and bespoke assay design, allowing labs to rapidly configure panels that meet their exact research or diagnostic needs without compromise.

In a field where diagnostic agility often dictates impact, YouSeq’s latest expansion turns the concept of a “test catalogue” into something far more dynamic—a molecular diagnostics smorgasbord that’s open, flexible, and ready to serve. Multiplexing is a powerful concept, but also technically complex, and of course, there are challenges in developing assays that can detect multiple targets accurately in one reaction. Wicks remarked “the biochemistry is the challenge. PCR is fundamentally about small pieces of DNA in a reaction binding to the right thing at the right time. As you multiplex more targets, the risk of inaccurate interactions between those molecules exponentially increases. So we’ve built bespoke in silo design tools to model these interactions. And then novel chemistries in our reaction mixes that minimize primer-primer interactions. Then we place a huge focus on real lab wet testing to make sure that every primer pair is performing perfectly.”

The bigger picture

The timing of YouSeq’s expansion reflects a wider industry shift toward customizable molecular testing and precision-driven workflows. As clinical and translational laboratories demand more data per run and faster test deployment, companies that can deliver modular, scalable assay systems are rising to prominence.

Traditional assay development pipelines—often constrained by fixed panels and long validation cycles—are increasingly giving way to on-demand molecular design. By enabling labs to build their own multiplex panels from an extensive menu of validated assays, YouSeq is tapping into a movement toward decentralized innovation, where flexibility, throughput, and cost efficiency drive adoption.

Wicks added ‘We’ve built a company, a culture and team that are focused on being world class at one thing and one thing only and that’s the best possible qPCR assays. During COVID, for example, we designed, verified, and validated a new COVID test in around eight days, which of course was unprecedented, but even in normal world conditions we can produce a new high functioning assay in around 10 weeks.”

As the pace of discovery accelerates across infectious disease and oncology, platforms like YouSeq’s—combining breadth, configurability, and readiness—are poised to shape the next generation of molecular diagnostics. Wicks concludes by saying the future of the diagnostics landscape holds great promise and opportunity for disruption “We have grand plans to develop a universal diagnostic test to cover all infectious disease as well as cancers and genetic disorders all in a single test.”